Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18935280 | 0.70 | GAA (0.36) | GAAMAPT | |
| SCHEMBL8855 | 0.67 | GAA (0.48) | GAAMAPT | |
| SCHEMBL452418 | 0.67 | GAA (0.48) | GAAMAPT | |
| Benzodiazepine SCHEMBL8137 | 0.64 | GAA (0.44) | GAAMAPT | |
| SCHEMBL2299949 | 0.64 | GAA (0.44) | GAAMAPT | |
| SCHEMBL208462 | 0.64 | GAA (0.44) | GAAMAPT | |
| Benzodiazepine SCHEMBL7160172 | 0.64 | GAA (0.44) | GAAMAPT | |
| SCHEMBL9934042 | 0.63 | GAA (0.43) | GAAMAPT | |
| SCHEMBL11428738 | 0.62 | GAA (0.48) | GAAMAPT | |
| SCHEMBL2386480 | 0.62 | MAPT (0.48) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109847-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-04-04 | — | — | US | claimed |
| EP-4267539-A1 | HISTONE DEACETYLASE INHIBITORS | The University of Queensland (AU) | 2023-11-01 | — | — | EP | claimed |
| CN-109326731-B | Organic light emitting device and electronic apparatus including the same | 三星显示有限公司 | 2023-04-28 | — | — | CN | claimed |
| US-20220409629-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION | PFIZER INC. | 2022-12-29 | — | — | US | claimed |
| EP-4051675-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-09-07 | — | — | EP | claimed |
| EP-4048665-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION | Reviral Limited (GB) | 2022-08-31 | — | — | EP | claimed |
| WO-2022133551-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-06-30 | — | — | WO | claimed |
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | claimed |
| EP-3662751-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2021-10-13 | — | — | EP | claimed |
| CN-107903208-B | Biaryl pyridine deubiquitinase inhibitor, preparation method and application thereof | 杭州市西溪医院 | 2021-09-03 | — | — | CN | claimed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| US-6432964-B1 | A THIENYLPYRIMIDINE COMPOUND | AGREVO UK LIMITED (GB) | 2002-08-13 | — | — | US | claimed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1051415-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-15 | — | — | EP | claimed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| CN-1234801-A | 3-carboxamide derivatives of 5H-pyrrolo [2, 1-C ] [1,4] -benzodiazepine * | AMERICAN HOME PROD (US) | 1999-11-10 | — | — | CN | claimed |
| WO-1999037637-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-29 | — | — | WO | claimed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| US-5391772-A | In presence of a dry aprotic solvent and proton acceptor | MERCK & CO., INC. (US) | 1995-02-21 | — | — | US | claimed |
| WO-1995001970-A1 | ALCOHOL TO AZIDE SN2 CONVERSION | MERCK & CO., INC. (US) | 1995-01-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409629-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION | GABRA1, GABRA3, CNR1 | GAA 4576/4885MAPT 3785/4885 |
| US-20240109847-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC11 | GAA 79/4885MAPT 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.